5CL-ADB-A (systematic name: methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate) is a potent synthetic cannabinoid agonist pivotal in receptor binding studies. Its high CB1 affinity (Ki = 0.24 nM) enables critical neurological research, including neuropathic pain modulation and addiction mechanisms. Pharmaceutical-grade 5cl-adb-a powder requires ≥99.5% HPLC purity with residual solvent limits below 50 ppm—standards enforced by leading analytical labs like Eurofins.
The synthesis begins with 5cladba precursor compounds, notably 5-chloro-1H-indole-3-carboxylic acid and tert-leucine methyl ester hydrochloride. Optimized coupling reactions (e.g., EDC/HOBt) yield high-purity intermediates, while crystallization from acetonitrile ensures batch consistency for 5cladba raw material production. For validated precursor suppliers, consult the WHO-compliant Chemical Sourcing Index [https://5cl-adb-a.com/].
China dominates global 5CL-ADB-A manufacturing, producing ~80% of the world’s supply through ISO 17025-accredited facilities in Shanghai and Guangdong. Strict adherence to REACH and FDA GMP protocols defines premium 5cladba china exports, with top suppliers offering COA-backed shipments. Regulatory landscapes remain volatile; 5CL-ADB-A is banned in 47 countries under synthetic cannabinoid analog laws.
Current research focuses on metabolite profiling (via LC-QTOF-MS) and stability under physiological conditions. Always verify jurisdictional compliance and use third-party purity testing. For peer-reviewed synthesis optimization, access the Journal of Forensic Sciences database [https://5cl-adb-a.com/].
